For the full analysisinclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citationsyou can view the complete report on MedRxiv or directly within Truveta Studio
Weight lossrelated bone mineral and muscle loss remain a concern
Foundayos pivotal trial places its average weight loss at around 12%, with some patients losing up to 15%, while Mounjaro at the highest dose averages around 20%
Beginners benefit from starting with REGEN rather than individual peptides because the combination is pre-mixed at optimal ratios, requires only one injection, and provides synergistic effects
Looking for support with medicines optimisation